Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Maternal Tdap Immunization in Guatemala

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02301702
Recruitment Status : Active, not recruiting
First Posted : November 26, 2014
Last Update Posted : July 18, 2019
Sponsor:
Collaborator:
Universidad del Valle, Guatemala
Information provided by (Responsible Party):
Saad B. Omer, MBBS, MPH, PhD, Emory University

Brief Summary:
Maternal immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) is a potential strategy to protect young infants against pertussis before they are fully vaccinated because maternal antibodies may cross the placenta and passively protect her infant. The proposed study is a randomized, blinded, controlled, vaccine trial of maternal Tdap vaccination during the third trimester of pregnancy (Tdap vaccination at 27-36 weeks gestation). Pregnant women will be recruited from the prenatal care clinics at the Hospital Nacional Occidente and the Health Centers in Quetzaltenango, La Esperanza, San Juan Ostuncalco and Concepción Chiquirichapa. Enrolled women and their infants will be followed up until 7 months post-partum.

Condition or disease Intervention/treatment Phase
Pertussis Whooping Cough Biological: Tdap Biological: Td Phase 2

Detailed Description:

The proposed study is a randomized, blinded, controlled, vaccine trial of maternal Tdap vaccination during the third trimester of pregnancy (Tdap vaccination at 27-36 weeks gestation). Pregnant women will be recruited from the prenatal care clinics at the Hospital Nacional de Occidente and the Health Centers in Quetzaltenango, La Esperanza, San Juan Ostuncalco and Concepción Chiquirichapa.

All healthy pregnant women between the ages of 18 and 40 years (inclusive) at 27 weeks gestation or later who are in the study areas will be eligible to participate in this study unless they meet one or more of the exclusion criteria. Pregnant women at <27 weeks gestation will be pre-screened and provided information about the study to encourage them to enroll later in their pregnancy. Women who are eligible will be enrolled after obtaining informed consent, and then they will be randomized to receive Tdap vaccine or Td vaccine. Enrolled women and their infants will be followed up until 7 months postpartum.

To address the primary objective, serum specimens will be collected from mothers prior to receiving the study product (Tdap or Td), within 72 hours after delivery and at 7 months post-partum. Moreover, infants specimens will be collected at delivery (cord blood or infant blood within 72 hours of birth), at 2 months of age (prior to the first dose of the routine childhood DTwP series), and at 7 months of age (approximately 4 weeks after the third dose of the routine DTwP series).

Infants will be given all three doses of the pentavalent vaccine which includes DTwP vaccine at 2, 4 and 6 months (routine childhood immunizations) as recommended by the immunization schedule of Guatemala's National Immunization Program.

Adverse events and serious adverse events will also be monitored.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 286 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Evaluation of Tdap in Pregnancy to Prevent Infant Pertussis
Study Start Date : July 2016
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Whooping Cough

Arm Intervention/treatment
Experimental: Tdap Vaccine
Combination Tetnus Toxoid, Reduced Diptheria Toxoid and Acellular Pertusis (Tdap)
Biological: Tdap
Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Other Name: Boostrix, Adacel

Active Comparator: Td Vaccine
Tetanus toxoid and reduced diphtheria toxoid vaccine (Td)
Biological: Td
The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala




Primary Outcome Measures :
  1. Infant pertussis antibody geometric mean concentrations (GMC) and 95% confidence intervals at birth (cord blood OR infant blood within 72 hours of birth), at 2 months of age, and 7 months of age [ Time Frame: Birth to 7 months of age ]
  2. Ratio of infant to mother pertussis antibody levels at the time of delivery [ Time Frame: Birth to 7 months of age ]
  3. Proportion of infants with at least a four-fold rise in serum antibody titer between 2 months and seven months of age (i.e., at four weeks after the 3rd dose of childhood DTwP) [ Time Frame: Birth to 7 months of age ]
  4. Maternal pertussis antibody GMC and 95% confidence intervals at baseline (pre-vaccination), within 72 hours after delivery, and seven months post-partum [ Time Frame: Pre-vaccination to 7 months post-partum ]
  5. Proportion of mothers sero-converting (serum pertussis antibody titer increase of ≥ 4-fold compared to pre-vaccination antibody levels) and 95% confidence intervals at the time of delivery (within 72 hours after delivery) and seven months post-partum [ Time Frame: Pre-vaccination to 7 months post-partum ]

Secondary Outcome Measures :
  1. Incidence of illnesses meeting the syndromic case definition (defined below); prematurity; pneumonia (per WHO Integrated Management of Childhood Illness [IMCI] classification) [ Time Frame: Birth to 7 months of age ]
  2. Birth weight and infant growth/anthropometric measurements (e.g., height and weight for age). [ Time Frame: Birth to 7 months of age ]
  3. Incidence of unsolicited non-serious (grades 1 & 2) adverse events 7 days post-delivery (for neonates) [ Time Frame: Birth to 7 months of age ]
  4. Infant growth/anthropometric measurements (e.g., height and weight z-scores at birth and 7 months of age) [ Time Frame: Birth to 7 months of age ]
  5. Incidence of serious (grades 3 & 4) adverse events through 7 months of age [ Time Frame: Birth to 7 months of age ]
  6. Laboratory (real-time PCR) confirmed pertussis infection in infants younger than 6 months of age [ Time Frame: Birth to 7 months of age ]
  7. Incidence of unsolicited non-serious (grades 1&2) AEs 28 days post vaccination [ Time Frame: Pre-vaccination to 7 months post-partum ]
  8. Incidence of serious (grades 3 & 4) adverse events through 7 months post-partum [ Time Frame: Pre-vaccination to 7 months post-partum ]
  9. Infant pertussis antibody geometric mean concentrations (GMC) and 95% confidence intervals at 19 months after delivery [ Time Frame: Pre-vaccination to 19 mo post-partum ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Pregnant woman in late second or third trimester of pregnancy (i.e., after 27 weeks gestation),
  2. Between the ages of 18 and 40 years (inclusive),
  3. Intends to remain in the study area for at least seven months after delivery,
  4. Has access to a mobile phone (defined as a phone in the possession of the participant or another family member with whom she lives),
  5. Able to provide informed consent. If participant is illiterate, procedures to ensure full understanding of the research and consent process will be implemented according to international and federal guidelines.

Exclusion Criteria:

  1. History of fever or oral temperature ≥ 38.0 degree Celsius within 48 hours prior to vaccination (women can be re-evaluated at a subsequent visit),
  2. Received Tdap vaccine in the previous year,
  3. History of serious systemic disease, including but not limited to: Guillain-Barré syndrome; known HIV, hepatitis B, or hepatitis C infection; heart/lung disease; uncontrolled diabetes mellitus (including gestational diabetes); chronic liver/kidney disease; clinically significant neurological disorders. This information will be based on self-reporting and (where possible) will be confirmed by health facility medical records.
  4. High risk pregnancy, as identified by the Normas de Atención en Salud Integral, a guideline document published by the Ministry of Health, and also any previous complicated pregnancy or preterm delivery, spontaneous or medical abortion, or previous congenital anomaly,
  5. Received immunoglobulin or other blood product within the preceding 3 month (with the exception of Rhogam),
  6. History of allergy to any component of the vaccines (i.e. eggs, egg proteins, gelatin, formaldehyde, glutaraldehyde, polyethylene glycol p-isooctylphenyl ether, sucrose, aluminum hydroxide, polysorbate 80) or to latex,
  7. History of severe reaction (including hypersensitivity) after receiving any vaccine,
  8. History or evidence of immunosuppression (due to illness or treatment) or is on immunosuppressive therapy (includes long term use of steroids; use of high-dose inhaled steroids within past six months; with the exception of treatment with betamethasone or dexamethasone injections for the prevention of lung immaturity in the last trimester of pregnancy,
  9. In the opinion of the study team - it would be unsafe or unsuitable for the pregnant mother or her fetus to receive the vaccine or participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02301702


Locations
Layout table for location information
Guatemala
Universidad del Valle de Guatemala
Guatemala, Guatemala, 01015
Sponsors and Collaborators
Emory University
Universidad del Valle, Guatemala
Investigators
Layout table for investigator information
Principal Investigator: Saad B. Omer, MBBS,MPH,PhD Emory University

Layout table for additonal information
Responsible Party: Saad B. Omer, MBBS, MPH, PhD, Associate Professor of Global Health, Epidemiology, and Pediatrics, Emory University
ClinicalTrials.gov Identifier: NCT02301702     History of Changes
Other Study ID Numbers: IRB00072201
First Posted: November 26, 2014    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019

Keywords provided by Saad B. Omer, MBBS, MPH, PhD, Emory University:
Maternal Immunization
Tdap
Td
Pertussis

Additional relevant MeSH terms:
Layout table for MeSH terms
Whooping Cough
Bordetella Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Respiratory Tract Infections
Infection
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs